Phenomenology of Postpartum Psychosis: Preliminary Findings from MGHP3
The MGHP3 study provides key insights into the onset, duration, treatment, and characteristics of postpartum psychosis in a large, diverse cohort.
The MGHP3 study provides key insights into the onset, duration, treatment, and characteristics of postpartum psychosis in a large, diverse cohort.
Individuals with postpartum depression are being recruited for a clinical trial of a novel psychedelic compound, RE104.
There is a wide range of barriers across multiple levels--individual, healthcare professional, interpersonal, organizational, political, and societal.
Further studies are needed to determine whether ketamine and esketamine are effective for the treatment of postpartum depression.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on access to perinatal mental healthcare with Ob.Gyn News on May 23, 2024.
A growing body of literature supports the reproductive safety of stimulants in pregnant women and suggests that not treating may have negative consequences for the mother and her child.
May 1, 2024 is World Maternal Mental Health Day, coming together to increase awareness of perinatal mood and anxiety disorders.
MamaLift Plus is a prescription-only digital therapeutic intervention for the treatment of mild to moderate postpartum depression using several different neurobehavioral interventions.
Establishing noninvasive and low-cost data collection based on childbirth narratives for the identification of women with CB-PTSD could serve as an important first step to complement more extensive methods.
Loss of at least one night’s sleep at the time of labor and delivery is a potent risk factor for postpartum psychosis in women with bipolar disorder.